Related references
Note: Only part of the references are listed.2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia
Ulf Landmesser et al.
EUROPEAN HEART JOURNAL (2018)
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial
Kausik K. Ray et al.
DIABETES OBESITY & METABOLISM (2018)
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
Luiz Sergio F. de Carvalho et al.
DIABETES CARE (2018)
2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways
Donald M. Lloyd-Jones et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial
Marc S. Sabatine et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Effect of LDL cholesterol, statins and presence of mutations on the prevalence of type 2 diabetes in heterozygous familial hypercholesterolemia
Elisenda Climent et al.
SCIENTIFIC REPORTS (2017)
Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: The ODYSSEY DM-INSULIN randomized trial
Lawrence A. Leiter et al.
DIABETES OBESITY & METABOLISM (2017)
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Alberico L. Catapano et al.
ATHEROSCLEROSIS (2016)
Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher
Henry N. Ginsberg et al.
CARDIOVASCULAR DRUGS AND THERAPY (2016)
Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study
Nathan D. Wong et al.
DIABETES CARE (2016)
No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies
Helen M. Colhoun et al.
EUROPEAN HEART JOURNAL (2016)
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Massimo F. Piepoli et al.
EUROPEAN HEART JOURNAL (2016)
Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials
Michel Farnier et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2016)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis
Luca A. Lotta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Lipid-lowering efficacy of the PCSK9 inhibitor evolocumab (AMG 145) in patients with type 2 diabetes: a meta-analysis of individual patient data
Naveed Sattar et al.
LANCET DIABETES & ENDOCRINOLOGY (2016)
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Marja-Riitta Taskinen et al.
ATHEROSCLEROSIS (2015)
Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial
Christopher P. Cannon et al.
EUROPEAN HEART JOURNAL (2015)
Association Between Familial Hypercholesterolemia and Prevalence of Type 2 Diabetes Mellitus
Joost Besseling et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial
Harold Bays et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2015)
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1-Full Report
Terry A. Jacobson et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2015)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Daniel I. Swerdlow et al.
LANCET (2015)
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Jennifer G. Robinson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: Rationale and design of the ODYSSEY Outcomes trial
Gregory G. Schwartz et al.
AMERICAN HEART JOURNAL (2014)
Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24 week, double-blind, randomized Phase 3 trial
Eli M. Roth et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2014)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS' COMPREHENSIVE DIABETES MANAGEMENT ALGORITHM 2013 CONSENSUS STATEMENT - EXECUTIVE SUMMARY
Alan J. Garber et al.
ENDOCRINE PRACTICE (2013)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2013)
Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study
L. A. Leiter et al.
DIABETIC MEDICINE (2011)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
Lipids and lipoproteins in patients with type 2 diabetes
RM Krauss
DIABETES CARE (2004)
Share Paper
